Paget disease of bone (PDB) is a bone metabolic disorder causing pain, fractures, and deformity. Its incidence is estimated to be 1 to 2% in Caucasians older than 55 years, but in Asian populations the incidence is rare. We report on 2 female and one male Japanese patients aged 46 to 73 years with PDB. One patient had monostotic disease with pain around the shoulder and the other 2 were asymptomatic. All patients had elevated alkaline phosphatase (ALP) levels (range, 629-957 U/L). Two patients responded to oral bisphosphonate treatment and achieved normalised ALP levels and pain relief. One patient with polyostotic disease did not show any change in ALP levels. The diagnosis of the disease and the indications for bisphosphonate treatment are discussed.
introduction
Paget disease of bone (PDB) impairs bone metabolism by increasing bone resorption and formation, and causes pain, fractures, and deformity (e.g. bowing of the long bones). The incidence of PDB is estimated to be 1 to 2% in Caucasians older than 55 years, but in Asian populations the incidence is rare. 1 According to the Japan Osteoporosis Society, the prevalence of PDB in Japan is 2.8 per million. 2 Japanese patients with PDB are often misdiagnosed. We report on 2 female and one male Japanese patients aged 46 to 73 years with PDB.
case reports patient 1
In February 2008, a 59-year-old woman was referred to our hospital for investigation of abnormal findings in bone scintigraphy and a 3-year history of elevated alkaline phosphatase (ALP) levels of >957 U/L (reference range according to the Japan Society of serum ALP level was monitored. The ALP level did not change over one year, so risedronate 17.5 mg/day was given for 8 weeks, but the ALP levels remained unchanged.
patient 2
In October 2009, a 46-year-old man was referred to our hospital for investigation of sharply elevated ALP levels from 584 to 711 U/L within one year and a 10-year history of elevated ALP levels (Fig. 2) , with otherwise normal liver function results. PDB or bone tumours (osteosarcoma, giant cell tumour, and metastatic bone tumour) were suspected. Radiographs showed erosive change of the C2 lamina (Fig. 2) . Bone scintigraphy revealed markedly increased uptake of 99m Tc-MDP in C2, L1, right proximal humerus, and left calcaneus (Fig. 2) . CT showed the enlarged C2 lamina with a thickened and 'fuzzy' cortex ( Fig. 2) . Magnetic resonance imaging demonstrated a hyperintense lesion in the C2 lamina. Positron emission tomography was performed to screen for cancerous lesions in the whole body. No primary tumour was detected in the internal organs, but moderate uptake was noted in C2, L1, right humerus, and left calcaneus. The maximum standard uptake value of the C2 lamina was 4.3, which is the cut-off value for malignant bone tumours. 4 Biopsy of the C2 lamina was performed to exclude malignant bone tumour. Fragile whitish tissue was obtained, with little bleeding. Irregular trabeculae interposed with fibrous tissues were noted (Fig. 2 ). There was a mixture of woven and lamellar bone known as the mosaic pattern. Osteoclasts were increased in number and size. The diagnosis of PDB was confirmed. The patient was treated with risedronate 17.5 mg/day for 8 weeks. The ALP level decreased at 3 months and were within the normal range at 6 months.
patient 3
In August 2009, a 73-year-old woman presented with pain around the left shoulder, deformity of the humerus, and elevated serum ALP levels of 825 U/L. Her humerus was thickened with a fuzzy cortex (Fig. 3) . Bone scintigraphy revealed marked uptake of the radionuclide in the left humerus. PDB and PDB-associated sarcoma were suspected (Fig.  3) . Biopsy of the left humerus was performed to exclude malignancy. The mosaic pattern of irregular fragments of trabeculae and increased numbers of reversal fronts and cement lines were noted (Fig. 3) . A diagnosis of monostotic PDB was made. The patient Clinical Chemistry, 115-359 U/L). Radiographs showed cortical hypertrophy and sclerotic changes in her skull and right pelvic bone (Fig. 1) . Bone scintigraphy revealed markedly increased uptake of 99m technetium-methylene diphosphonate ( 99m Tc-MDP) in the affected bones, including the skull, clavicle, ilium, and femur (Fig. 1) . Computed tomography (CT) demonstrated thickened cortex and irregular sclerosis of the cancellous bones (Fig.  1) . PDB was suspected, and biopsy of the ilium was performed to exclude malignant bone tumour. Although irregular cement lines were observed in the trabeculae, other findings of PDB such as increased number of osteoclasts or thickened trabeculae were not present. Tetracycline double-labelling analysis showed increased reabsorption of the surfaces of the trabeculae, which is a sign of hyper-remodelling. 3 The diagnosis of PDB was confirmed. The patient was treated with etidronate 200 mg/day, and her was treated with bisphosphonate (risedronate 17.5 mg/week). As the patient had a history of gastritis, there was a concern about peptic disorder secondary to bisphosphonate treatment. Three months after treatment, the ALP level decreased to within the normal range. The pain in the upper arm was relieved after 2 months of treatment. At 6 months, radiographs showed a fuzzy and thickened cortex. Bone scintigraphy showed reduced accumulation of nucleotide in the left humerus.
discussion
Radionuclide bone scanning enables identification of PDB-affected bones. 5 Measuring serum ALP levels enables screening for PDB. In this report, patients 1 and 2 had a history of elevated ALP levels for 3 and 10 years, respectively, but the diagnosis was delayed owing to the rarity of PDB in Asian countries. A guideline for the diagnosis and management of PDB may help to identify Asian patients with undiagnosed PDB. 6 PDB is common in Caucasians, but is rare in Asians. 2, 7 These ethnic differences suggest a genetic factor in its aetiology. Mutations in the TNFRSF11A gene (which encodes receptor activator of nuclear factor kappa B [NFκB, RANK]), TNFRSF11B gene (which encodes osteoprotegerin), valosin-containing protein gene (which encodes p97), and sequestosome 1 (SQSTM1) gene (which encodes p62) have been reported in patients with PDB. 8 p62 is a scaffold protein that plays an important role in regulating NFκB signalling downstream of the interleukin-1 receptor, tumour necrosis factor receptor, RANK receptor, and nerve growth factor receptor. 9 The SQSTM1 gene is most important for the development of PDB, because mutations in p62 stimulate osteoclast function. 9 Patients with SQSTM1 gene mutations have more extensive disease.
1 Genetic analysis may be useful for diagnosis and prediction of the outcome of PDB.
Drug therapy for asymptomatic patients is controversial. The main indication for medical treatment of PDB is bone pain. 1, 6 Early treatment for young patients in the osteolytic phase is necessary, as PDB may induce skeletal deformities, arthritis, or pathological fractures. 10 Neurologic symptoms are a complication of PDB. The primary mechanisms of spinal nerve damage are ischaemic myelitis and compression secondary to bone hypertrophy. 11 Involvement of the skull can cause neurological complications, including hearing loss, which is not reversible by medical treatment. 12 Therefore, prevention of neurologic complications is another indication for medical treatment. 10 The long-term benefit of medical treatment for asymptomatic PDB is unknown.
Bisphosphonates are the treatment of choice for PDB, as they suppress increased bone resorption, leading to normalisation of serum ALP levels. 6, 10, 13 Oral (etidronate, alendronate, tiludronate, and risedronate) and intravenous (pamidronate and zoledronic acid) bisphosphonates have been approved by the US Food and Drug Administration for treatment of PDB, 13, 14 but in Japan only etidronate and risedronate are approved. The first-generation etidronate has been shown to reduce the ALP concentration to a normal level in only 29% of patients. 14 Risedronate is a nitrogen-containing bisphosphonate and can achieve normal ALP levels in 73% of patients.
14 Nine of 11 Japanese patients with PDB showed reduction in serum ALP levels to within the normal range after risedronate treatment. 15 In this report, 2 of the patients responded to bisphosphonate treatment and the ALP level decreased to within the normal range (Fig. 4) . Patients with PDB involving the skull showed a marked increase in bone turnover and a lower response to therapy. 16 The treatment effect is affected by the clinical background, biochemical data, or genetic condition.
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